Science

Yan Leyfman

Apr 7, 2025, 10:59

Yan Leyfman: LILRB1 CAR-T as a promising next-gen therapy for blood cancers

Yan Leyfman, Co-founder and executive director of MedNews Week, shared an article by Katsiaryna Marhelava, et al. on LinkedIn:

“CD19 CAR-T cells have revolutionized treatment for relapsed/refractory B-cell malignancies—but up to 50% of patients relapse, often due to CD19 antigen loss or lineage switching.

In search of a new target, researchers identified LILRB1 (CD85j) via cell surface proteomics from high-risk B-ALL patient samples.

Why LILRB1?

Expressed on monocytes & B-cells.
Stably present in B-ALL & B-NHL—even after CD19/CD20-based therapies.
Notably expressed in monocytic AML too.

LILRB1 CAR-T cells showed: Antigen-specific killing of B-ALL/B-NHL cells (even CD19-resistant ones).

In vivo efficacy in B-ALL xenograft models.
Cytotoxicity against AML cells in vitro & in vivo.

These findings position LILRB1 CAR-T as a promising next-gen therapy for blood cancers, including those resistant to current immunotherapies.

Time to rethink the frontline in CAR-T innovation.”

LILRB1-directed CAR-T cells for the treatment of hematological malignancies.

Authors: Katsiaryna Marhelava, et al.

Yan Leyfman: LILRB1 CAR-T as a promising next-gen therapy for blood cancers

AML B-cell malignancies blood cancers cancer CD19 CD19 CAR-T cells cytotoxicity fight against cancer Global fight against cancer hematological malignancies Katsiaryna Marhelava LILRB1 CAR-T MedNews Week OncoDaily Oncology Yan Leyfman

Can Joe Lonsdale Become the Elon Musk of FDA Reform?

In Memory of Robert Kardashian: His Courageous Battle with Esophageal Cancer

The Essential Medicines for Children with Cancer: From Access to Action by OncoDaily

Martin Makary Becomes the 27th FDA Commissioner

OncoBillionaires of 2025: The Titans Behind the Cancer Revolution